secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K/A
Filed at:   2025-07-08T23:59:59+00:00
Accession:  0001178913-25-002335
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion amends 8-K, delays Nasdaq transfer; reverse split expected in August to cure bid price deficiency
--------------------------------------------------------------------------------

- Nasdaq transfer to Capital Market not on July 8 as originally reported; now expected as soon as practicable.
- Shareholder vote on 1-for-15 reverse split reconvenes July 14, 2025 at annual meeting.
- After approval, 10-day Nasdaq notice period ends ~July 25; then 10 consecutive trading days above $1.00 needed.
- Compliance with minimum bid price rule expected early to mid-August; no assurance of success.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325002335/0001178913-25-002335-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325002335/zk2533427.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-002335

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer